Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists (open access)

Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists

This article presents a novel class of chemically identical theranostic small-molecule prodrug conjugates (T-SMPDCs), [¹⁸/¹⁹F]F-TZ(PSMA)-LEGU-TLR7, for PSMA-targeted delivery and controlled release of toll-like receptor 7 (TLR7) agonists to elicit de novo immune response for cancer immunotherapy. The proof-of-concept biological evaluation presented demonstrates the potential of T-SMPDCs for cancer immunomodulatory therapies.
Date: June 28, 2022
Creator: Debnath, Sashi; Hao, Guiyang; Guan, Bing; Thapa, Pawan; Hao, Justin; Hammers, Hans et al.
System: The UNT Digital Library